Substudy of ADVOCATE Trial for ANCA-Associated Vasculitis Finds Avacopan Reduces Need for Glucocorticoids, Respiratory and ENT Involvement

Avacopan was better than prednisone in reducing respiratory as well as ear, nose and throat (ENT) involvement and enabled reduced glucocorticoid use in ANCA-associated vasculitis patients participating in the phase 3 ADVOCATE trial. Study results were published at the ATS 2022 international conference. The study was a subgroup analysis of results from the larger trial, which led to FDA approval of avacopan.

Vasculitis Foundation’s Young Investigator Award Goes to Monash University Research Fellow

Dragana Odobasic, PhD, a research fellow at Monash University in Melbourne, Australia, was awarded the Vasculitis Foundation’s (VF) “Dr. Chris Cox-Marinelli Young Investigator Award” in May for her study, Tolerogenic Dendritic Cells for Antigen-Specific Immunosuppression in MPO-ANCA Vasculitis. The award, a one-year grant totaling $49,822, was created in memory of Chris Cox-Marinelli, MD, who was a strong advocate for promoting the development of junior investigators toward a career in vasculitis.